Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Madhav R Seshadri, Lorena Fontan, Prasanna Sreevatsan, David Scott, John Hatcher, Guangyan Du, Min Xia, Ilkay Us, Nathanael Gray, Ari Melnick

Blood (2021) 138 (Supplement 1): 269.

https://doi.org/10.1182/blood-2021-153855

Published: 2021

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Ken Morita, MD PhD, Shuning He, PhD, Radosław P. Nowak, PhD, Jinhua Wang, PhD, Nathanael Gray, PhD, Eric S. Fischer, PhD, A. Thomas Look, MD

Blood (2019) 134 (Supplement_1): 406.

https://doi.org/10.1182/blood-2019-123573

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Guang Yang, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Amanda Kofides, Lian Xu, MS, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael Gray, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 394.

https://doi.org/10.1182/blood-2019-130636

Published: 2019

Journal Articles

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Shan Lin, Yusuke Tarumoto, Jinhua Wang, PhD, Joseph Milazzo, Yali Xu, Nathanael Gray, Christopher Vakoc, Kimberly Stegmaier, MD

Blood (2019) 134 (Supplement_1): 3941.

https://doi.org/10.1182/blood-2019-125278

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Journal Articles

Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Christopher J. Ott, PhD, Raphael Szalat, MD, Matthew Lawlor, Mehmet Kemal Samur, PhD, Yan Xu, MD, Charles B Epstein, Charles Y Lin, PhD, Rao Prabhala, PhD, Nina Farrell, Lauren D Walter, Logan Schwartz, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Jinhua Wang, PhD, Nathanael Gray, PhD, Kenneth Anderson, MD, Richard A. Young, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 1313.

https://doi.org/10.1182/blood-2018-99-119941

Published: 2018

Journal Articles

Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors — Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications

Ryosuke Shirasaki, MD, Ricardo De Matos Simoes, PhD, Geoffrey Matthews, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Olga Dashevsky, PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Tinghu Zhang, PhD, Megan Bariteau, Jeffrey Sorrell, BA, Nicholas P Kwiatkowski, PhD, Nathanael Gray, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 3343.

https://doi.org/10.1182/blood.V130.Suppl_1.3343.3343

Published: 2017

Journal Articles

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

Blood (2017) 130 (Supplement 1): 1212.

https://doi.org/10.1182/blood.V130.Suppl_1.1212.1212

Published: 2017

Journal Articles

A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells

Guang Yang, PhD, John Hatcher, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji Chen, BS, Lian Xu, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Gloria Chan, MS, Zachary Hunter, PhD, Christopher Patterson, MAcc, Joshua Gustine, Jorge J. Castillo, MD, Nathanael Gray, PhD, Steven P Treon, MDPhDFRCP, Sara Buhrlage, PhD

Blood (2017) 130 (Supplement 1): 719.

https://doi.org/10.1182/blood.V130.Suppl_1.719.719

Published: 2017

Journal Articles

A Unique N-Phenylbenzamide Inhibitor Targeting Non-Receptor Tyrosine Kinases Potently Suppresses AML Cell Growth In Vitro and In Vivo

Mark C Weir, PhD, Sherry Shu, PhD, Sabine Hellwig, PhD, Ravi Patel, Li Chen, PhD, Li Tan, PhD, Nathanael Gray, PhD, Thomas Smithgall, PhD

Blood (2017) 130 (Supplement 1): 3813.

https://doi.org/10.1182/blood.V130.Suppl_1.3813.3813

Published: 2017

Journal Articles

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Sara Buhrlage, PhD, Ellen Weisberg, MD, Nathan Schauer, Jing Yang, PhD, Ilaria Lamberto, PhD, Laura Doherty, Atsushi Nonami, MDPhD, Amanda L. Christie, BS, David M. Weinstock, MD, Richard M. Stone, MD, Nathanael Gray, PhD, James D Griffin, MD

Blood (2016) 128 (22): 524.

https://doi.org/10.1182/blood.V128.22.524.524

Published: 2016

Journal Articles

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

Fiona C Brown, PhD, Eric Still, Paolo Cifani, PhD, Casie Reed, Scott Ficarro, PhD, Jie He, PhD, Richard Koche, PhD, Patrick Bhola, PhD, Peter Romanienko, PhD, Willie Mark, PhD, Andrei V. Krivtsov, PhD, Anthony Letai, MD PhD, Nathanael Gray, PhD, Jarrod Marto, PhD, Scott A. Armstrong, MD PhD, Alex Kentsis, MD PhD

Blood (2016) 128 (22): 436.

https://doi.org/10.1182/blood.V128.22.436.436

Published: 2016

Journal Articles

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara J. Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael Gray, Steven P. Treon

Blood (2016) 127 (25): 3237–3252.

https://doi.org/10.1182/blood-2016-01-695098

Published: 2016

Journal Articles

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Philip Cohen, Li Tan, PhD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 4004.

https://doi.org/10.1182/blood.V126.23.4004.4004

Published: 2015

Journal Articles

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

Xia Liu, MD, Zachary Hunter, PhD, Lian Xu, Jie Chen, PhD, Jiaji Chen, Nicholas Tsakmaklis, Christopher J Patterson, MFA, Jorge J Castillo, MD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2015) 126 (23): 1563.

https://doi.org/10.1182/blood.V126.23.1563.1563

Published: 2015

Journal Articles

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Guang Yang, PhD, Sara Buhrlage, PhD, Li Tan, PhD, Xia Liu, MD, Jie Chen, PhD, Zachary Hunter, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Wei Zhang, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 705.

https://doi.org/10.1182/blood.V126.23.705.705

Published: 2015

Journal Articles

Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia

Blood (2015) 126 (23): 88.

https://doi.org/10.1182/blood.V126.23.88.88

Published: 2015

Journal Articles

Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors

Pannee Praditsuktavorn, MD, Benet Pera, PhD, Nicholas Kwiatkowski, PhD, ShaoNing Yang, MS, Tinghu Zhang, PhD, Nathanael Gray, PhD, Leandro Cerchietti, MD

Blood (2014) 124 (21): 810.

https://doi.org/10.1182/blood.V124.21.810.810

Published: 2014

NARROW

MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors — Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications

Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells

A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells

A Unique N-Phenylbenzamide Inhibitor Targeting Non-Receptor Tyrosine Kinases Potently Suppresses AML Cell Growth In Vitro and In Vivo

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia

Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only